Peer-reviewed veterinary case report
How Sonazoid Ultrasound Helps Detect Malignant Liver Lesions in Dogs
By Kanemoto, Hideyuki et al.·Published in Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·2009·Department of Veterinary Internal Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Characterization of canine focal liver lesions with contrast-enhanced ultrasound using a novel contrast agent-sonazoid.
- Species:
- dog
Plain-English summary
A group of 25 dogs with liver masses underwent a special ultrasound using a new contrast agent called Sonazoid to help identify whether the lesions were cancerous or benign. The results showed that all malignant lesions had a specific pattern that indicated they were cancerous, while most benign lesions did not. This method proved to be very effective, with a 100% success rate in identifying cancerous lesions. The study suggests that using Sonazoid could improve the diagnosis of liver problems in dogs, potentially leading to better treatment options.
People also search for: dog liver mass diagnosis · canine liver cancer ultrasound · Sonazoid for dogs liver lesions
Abstract
Contrast-enhanced ultrasound using Sonazoid, a novel contrast medium with a liver-specific Kupffer phase, was evaluated in canine focal liver lesions Twenty-five dogs with a liver mass were given intravenous Sonazoid, and the enhancement pattern in the arterial, portal, and parenchymal phase was characterized. An enhancement defect in the lesion in the parenchymal phase was observed in all malignant lesions, whereas only one of nine benign lesions had a filling defect. The diagnostic value of the presence of a filling defect for malignancy was statistically significant (100% sensitivity, 88.9% specificity, 94.1% positive predictive value, 100% negative predictive value), and was equal to that of hypoenhancement in the portal or delayed phase. The defect pattern (clear or irregular defect) was dependent (P < 0.05) on the types of malignancy (i.e., hepatocellular carcinoma and other types of malignancies). In the arterial phase, five of the six hepatocellular carcinomas had hypervascularity, whereas no other lesion was characterized by hypervascularity. In some dogs, additional lesions that could not be observed with conventional B-mode ultrasonography were detected in the parenchymal phase. The enhancement pattern of Sonazoid, especially in the parenchymal phase, has potential as a diagnostic tool for canine focal liver lesions.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/19400467/